Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
A 10 week evaluation, crossover design study including a 3 week washout period between
treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate
0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol
maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.